Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity

Biochimica et Biophysica Acta - Biomembranes

Volumn 1808, Issue 6, 2011, Pages 1567-1573

  Haro, I ^b   Gomara M J ^b   Galatola, R ^b   Domenech O ^a   Prat, J ^a   Girona, V ^a   Busquets, M A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

AFM; GBV C; HIV 1; Lipid monolayer; Peptidepeptide binding

Indexed keywords

AMPHOLYTE; ARGINYLPHENYLALANYLPROLYLPHENYLALANYLHISTIDINYLARGINYLCYSTEINYLGLYCYLALANYLGLYCYLPROLYLLYSYLLEUCYLTHREONYLLYSYLASPARTYLLEUCYLGLUTAMIC ACID; GLYCOPROTEIN GP 41; LIPOSOME; PHOSPHOLIPID; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; WATER;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL MEMBRANE; CELL VACUOLE; HEPATITIS G VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCUBATION TIME; INHIBITION KINETICS; LIPID BILAYER; LIPID MONOLAYER; MEMBRANE FUSION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; VIRUS VIRULENCE;

ALGORITHMS; AMINO ACID SEQUENCE; GB VIRUS C; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; KINETICS; LIPID BILAYERS; MICROSCOPY, ATOMIC FORCE; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHOLIPIDS; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; VIRAL PROTEINS;

GB VIRUS C; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79954797673     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2011.02.019     Document Type: Article

References (35)

1. H.M.H. Mostafa, P. Ali-Akbar, M. Minoo, S. Zahra, A. Sedigheh, A. Mahnaz, S. Shahram, N. Mahin, and M. Reza Evaluation of circulating natural type 1 interferon-producing cells in HIV/GBV-C and HIV/HCV coinfected patients: a preliminary study Arch. Med. Res. 38 2007 868 875
2. H.L. Tillmann, T. Kaiser, Z. Fox, S. Staszewski, F. Antunes, A. Monforte, P. Vernazza, A. Hill, U.B. Dragsted, and J.D. Lundgren Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial J. Acquir. Immune Defic. Syndr. 40 2005 378 380 (Pubitemid 41533082)
3. C.F. Williams, D. Klinzman, T.E. Yamashita, J. Xiang, P.M. Polgreen, C. Rinaldo, C. Liu, J. Phair, J.B. Margolick, and D. Zdunek Persistent GB-virus C infection and survival in HIV-infected men N. Engl. J. Med. 350 2004 981 990 (Pubitemid 38269275)
4. M.D. Berzsenyi, D.S. Bowden, S.K. Roberts, and P.A. Revill GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease J. Gastroenterol. Hepatol. 24 2009 1407 1410
5. M.D. Berzsenyi, D.S. Bowden, and S.K. Roberts GB virus C: insights into co-infection J. Clin. Virol. 33 2005 257 266 (Pubitemid 40982513)
6. P. Björkman, L. Flamholc, V. Molnegren, A. Marshall, N. Güner, and A. Widell Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART AIDS 21 2007 1641 1643 (Pubitemid 47075487)
7. M. Fernández-Vidal, M.D. Cubero, G. Ercilla, M.J. Gomara, and I. Haro I. Application of a chimeric synthetic peptide in the development of a serologic method for the diagnosis of hepatitis G virus infection Protein Pept. Lett. 14 2007 865 870 (Pubitemid 350013823)
8. M.J. Gomara, and I. Haro Synthetic peptides for the immunodiagnosis of human diseases Cur Med. Chem. 14 2007 531 546 (Pubitemid 46477726)
9. W.B. Supapol, R.S. Remis, J. Raboud, M. Millson, J. Tappero, R. Kaul, P. Kulkarni, M.S. McConnell, P.A. Mock, and M. Culnane Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection J. Infect. Dis. 197 2008 1369 1377 (Pubitemid 351706459)
10. J.T. Stapleton, K. Chaloner, J. Zhang, D. Klinzman, I.E. Souza, J. Xiang, A. Landay, J. Fahey, R. Pollard, and R. Mitsuyasu GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy AIDS 23 2009 605 610
11. E.L. Mohr, and J.T. Stapleton GB virus type C interactions with HIV: the role of envelope glycoproteins J. Viral. Hepat. 16 2009 757 768
12. S. Mazzini, M. Fernandez-Vidal, V. Galbusera, F. Castro-Roman, M.C. Bellucci, E. Ragg, and I. Haro 3D-Structure of the interior fusion peptide of HGV/GBV-C by 1H NMR, CD and molecular dynamics studies Arch. Biochem. Biophys. 465 2007 187 196 (Pubitemid 47287679)
13. E. Herrera, M.J. Gomara, S. Mazzini, E. Ragg, and I. Haro Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide J. Phys. Chem. B 113 2009 7383 7391
14. O. Fontvila, C. Mestres, M. Munoz, I. Haro, M.A. Alsina, and M. Pujol Surface behavior and peptide-lipid interactions of the E1(3-17)R and E1(3-17)G peptides from E1 capsid protein of GBV-C/HGV virus Coll. Surf. A Physicochemical Eng. Aspects 321 2008 175 180
15. S. Pérez-Lopez, M. Nieto-Suarez, C. Mestres, M.A. Alsina, I. Haro, and N. Vila-Romeu Behaviour of a peptide sequence from the GB virus C/hepatitis G virus E2 protein in Langmuir monolayers: its interaction with phospholipid membrane models Biophys. Chem. 141 2009 153 161
16. E. Herrera, S. Tenckhoff, M.J. Gomara, R. Galatola, M.J. Bleda, C. Gil, G. Ercilla, J.M. Gatell, H.L. Tillmann, and I. Haro Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus Type 1 infection J. Med. Chem. 53 2010 6054 606316
17. K. El Kirat, S. Morandat, and Y.F. Dufrene Nanoscale analysis of supported lipid bilayers using atomic force microscopy Biochim. Biophys. Acta 1798 2010 750 765
18. O. Domenech, G. Francius, P.M. Tulkens, F. Van Bambeke, Y. Dufrêne, and M.P. Mingeot-Leclercq Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization Biochim. Biophys. Acta 1788 2009 1832 1840
19. K.J. Weronski, P. Cea, I. Diez-Pérez, M.A. Busquets, J. Prat, and V. Girona Time-lapse atomic force microscopy observations of the morphology, growth rate, and spontaneous alignment of nanofibers containing a peptide-amphiphile from the hepatitis G virus (NS3 Protein) J. Phys. Chem. B 114 2010 620 625
20. M. Rafalski, J.D. Lear, and W.F. DeGrado Phospholipid interactions of synthetic peptides representing the N-terminus of HIV gp41 Biochemistry 29 1990 7917 7922 (Pubitemid 20281241)
21. N. Rojo, M.J. Gómara, M.A. Busquets, M.A. Alsina, and I. Haro Interaction of E2 and NS3 synthetic peptides of GB virus C with model lipid membranes Talanta 60 2003 395 404
22. W.C. Wimley, and S.H. White Designing transmembrane alpha-helices that insert spontaneously Biochemistry 39 2000 4432 4442 (Pubitemid 30212660)
23. M.J. Gomara, M. Lorizate, N. Huarte, I. Mingarro, E. Perez-Paya, and J.L. Nieva Hexapeptides that interfere with HIV-1 fusion peptide activity in liposomes block GP41-mediated membrane fusion FEBS Lett. 580 2006 2561 2566 (Pubitemid 44294500)
24. M.J. Sanchez-Martin, I. Haro, M.A. Alsina, M.A. Busquets, and M. Pujol A Langmuir monolayer study of the interaction of E1(145-162) Hepatitis G virus peptide with phospholipid membranes J. Phys. Chem. B 114 2010 448 456
25. M.K. Callahan, P.M. Popernack, S. Tsutsui, L. Truong, R.A. Schlegel, and A.J. Henderson Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cell J. Immunol. 170 2003 4840 4845 (Pubitemid 36519995)
26. G. Ma, T. Greenwell-Wild, K. Lei, W. Jin, J. Swisher, N. Hardegen, C.T. Wild, and S.M. Wahl Secretory leukocyte protease inhibitor binds to annexin II a cofactor for macrophage HIV-1 infection J. Exp. Med. 200 2004 1337 1346 (Pubitemid 39552574)
27. H. Garg, and R. Blumenthal Role of HIV gp41 mediated fusion/hemifusion in bystander apoptosi Cell. Mol. Life Sci. 65 2008 3134 3144
28. N. Lev, Y. Fridmann-Sirkis, L. Blank, A. Bitler, R.F. Epand, R.M. Epand, and Y. Shai Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action Biochemistry 48 2009 3166 3175
29. P. Calvez, S. Bussières, E. Demers, and C. Salesse Parameters modulating the maximum insertion pressure of proteins and peptides in lipid monolayers Biochimie 91 2009 718 733
30. D. Marsh Lateral pressure in membranes Biochim Biophys. Acta 1286 1996 183 193
31. R. Pascual, M. Contreras, A. Fedorov, M. Prieto, and J. Villalain Interaction of a peptide derived from the N-heptated repeat region of gp41 Env ectodomain with model membranes. Modulation phospholipid phase behavior Biochemistry 44 2005 14275 14288 (Pubitemid 41533052)
32. M.R. Moreno, M. Giudici, and J. Villalain The mebranotropic regions of the endo and ecto domains of HIV gp41 envelope glycoprotein Biochim. Biophys. Acta 1758 2006 111 123 (Pubitemid 44262107)
33. Y. Kliger, S.A. Gallo, S.J. Peisajovich, I. Muñoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai Mode of action of an antiviral peptide from HIV-1 J. Biol. Chem. 12 2001 1391 1397
34. A. Bitler, N. Lev, Y. Fridmann-Sirkis, L. Blank, S.R. Cohen, Y. Shai, and S. Yechiel Kinetics of interaction of HIV fusion protein (gp41) with lipid membranes studied by real-time AFM imaging Ultramicroscopy 110 2010 694 700
35. K. Sackett, M.J. Nethercott, R.F. Epand, R.M. Epand, D.R. Kindra, Y. Shai, and D.P. Keliky Comparative analysis of membrane-associated fusion peptide secondary structure of HIV gp41 constructs that model the early pre-hairpin intermediate and final hairpin conformations J. Mol. Biol. 397 2010 301 315